Pharma Stocks Review -- Eli Lilly, Zogenix, GlaxoSmithKline, Novo Nordisk, and Valeant Pharma Intl.

LONDON, August 21, 2014 /PRNewswire/ --

The trading session on Wednesday, August 20, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,979.13, up 0.35% and the NASDAQ Composite closed at 4,526.48, down 0.02%. The S&P 500 finished the day 0.25% higher at 1,986.51. During the trading session, eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 726.51, up 0.01%, and the index has advanced 8.10% in the previous three months. Investor-Edge has initiated coverage on the following equities: Eli Lilly and Co. (NYSE: LLY), Zogenix Inc. (NASDAQ: ZGNX), GlaxoSmithKline PLC (NYSE: GSK), Novo Nordisk A/S(NYSE: NVO) and Valeant Pharmaceuticals International Inc. (NYSE: VRX). Free research on these five companies can be accessed at:

http://investor-edge.com/register

Eli Lilly and Co.'s stock edged 0.24% lower on Wednesday, ending the session at $62.01. A total of 2.08 million shares were traded, below its three months average volume of 3.66 million shares. The stock moved between $61.67 and $62.24 during the session. Shares in Eli Lilly and Co. have gained 1.92% in the previous three trading sessions and 21.59% from the beginning of 2014. However, the company's shares have declined 2.30% in the last one month. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $61.83 is above its 200-day moving average of $57.05. Furthermore, Eli Lilly and Co.'s stock traded at a PE ratio of 19.27 and has a Relative Strength Index (RSI) of 53.63. Sign up and read the free notes on LLY at:

http://www.Investor-Edge.com/LLY-21Aug2014

Shares in Zogenix Inc. gained 0.83% on Wednesday, closing the day at $1.21. The stock recorded a trading volume of 1.28 million shares, which was below its three months average volume of 2.49 million shares. The stock oscillated between $1.19 and $1.22 during the session. Shares in Zogenix Inc. have fallen by 5.47% in the previous three trading sessions and 26.22% in the last one month. Additionally, the company's shares have lost 64.83% since the start of this year. Shares in Zogenix Inc. are trading below their 50-day and 200-day moving averages of $1.66 and $2.84, respectively. Moreover, the stock has an RSI of 28.16. The complimentary notes on ZGNX can be downloaded as in PDF format at:

http://www.Investor-Edge.com/ZGNX-21Aug2014

On Wednesday, shares in GlaxoSmithKline PLC advanced 0.97%, closing the day at $47.81. The stock recorded a trading volume of 5.29 million shares, much above its three months average volume of 2.98 million shares. The stock oscillated between $47.30 and $47.83 during the session. Shares in GlaxoSmithKline PLC have gained 2.01% in the previous three trading sessions, although, the shares have declined 11.00% in the last one month and 10.45% since the start of this year.GlaxoSmithKline PLC's shares are trading below their 50-day and 200-day moving averages of $51.45 and $53.11, respectively. Additionally, the stock has an RSI of 35.09. Register for free on Investor-Edge and access the latest research on GSK at:

http://www.Investor-Edge.com/GSK-21Aug2014

Shares in Novo Nordisk A/S fluctuated between $45.25 and $45.74 before ending Wednesday's session 0.99% higher at $45.69. The stock reported a trading volume of 0.87 million shares, which was at par its three months average volume. Shares in Novo Nordisk A/S have advanced 2.42% in the previous three trading sessions and 0.64% in the last one month. Additionally, the company's shares have mapped gains of 23.65% on YTD basis. Shares in Novo Nordisk A/S are trading above their 50-day and 200-day moving averages of $45.55 and $42.05, respectively. Further, the company's shares have an RSI of 51.37. The complete research on NVO is available for free at:

http://www.Investor-Edge.com/NVO-21Aug2014

On Wednesday, shares in Valeant Pharmaceuticals International Inc. recorded a trading volume of 1.78 million shares, which was below its three months average volume of 3.30 million shares. The stock finished the day at $113.10, which was 0.55% lower its previous day's closing of $113.72, and registered an intraday range of $112.33 and $114.12. Over the previous three trading sessions, shares in Valeant Pharmaceuticals International Inc. have advanced 0.75%, while the stock has fallen by 7.27% in the last one month and 3.66% on YTD basis. Shares in Valeant Pharmaceuticals International Inc. are trading below their 50-day and 200-day moving averages of $119.59 and $124.97, respectively. Furthermore, the stock has an RSI of 46.59. Free in depth research on VRX is available at:

http://www.Investor-Edge.com/VRX-21Aug2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by RohitTuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by RohitTuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.Investor-Edge.com

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED